Global office locator

Meet the ICON team at SCDM #EMEA26, to discover how we are driving innovation in clinical data science and helping organisations build smarter, more resilient clinical programmes. Visit us at booth 11 to explore how IC...

What is it really like to build a career as a Senior Clinical Research Associate at ICON? In our latest careers blog, Rafi Cabral, MD ,CCRP shares his experience of life as a CRA, from partnering with study sites and su...

Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our free monthly publication b...

Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...

Oligonucleotide (ON) drug development is accelerating rapidly—but first in human (FIH) studies remain complex. Join our upcoming webinar to explore key translational and clinical considerations for initiating FIH antis...

Faster study start up starts with the right sites, and the right tools. Speak with us at ASCO, booth \#35093 to learn about ICON’s purpose built technology suite that helps sponsors identify, activate and collaborate wi...

Great discussion recently at European Pharmaceutical Review’s webinar, “Harnessing AI for more efficient clinical trials.” ICON’s SVP of Enterprise AI, Tony Clarke, joined a panel of industry leaders to share perspectiv...

ICON proudly supports World Immunisation Week. In our new vaccine whitepaper, ICON experts discuss how planning for long-term follow-up early in the vaccine development process is critical to effectively collecting and u...

Selecting the right evidence generation method NMA, MAIC, STC and ML NMR each have distinct advantages and limitations. Our whitepaper provides a comparative overview to help researchers and sponsors choose the most a...

Patient safety and data integrity are the primary concerns in early phase clinical trials. In the US sponsors generally follow one of two standards sets when conducting early phase trials: Good Manufacturing Practice (GM...

On 5 May at SCDM EMEA, ICON’s Kevin Devenny will chair a session exploring why strong business processes and culture still matter, even as automation and AI continue to advance. The session will consider why technology ...

ICON Biotech will be at #OCTEU26 in Barcelona on 6–7 May. The conference unites biotech and clinical research leaders to explore the scientific and strategic forces shaping clinical development. Our biotech dedicated mo...